Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cider supplement recall

This article was originally published in The Tan Sheet

Executive Summary

Port Washington, N.Y.-based Confidence Inc. has initiated a voluntary recall of one lot of Metaboslim Apple Cider Vinegar brand dietary supplement (lot #3001006) because it contains an undeclared drug ingredient, FDA announces Aug. 17. The agency informed the firm that lab analysis of samples of the supplement found it contained undeclared sibutramine, an FDA-approved drug used as an appetite suppressant for weight loss. The affected lot was primarily sold in Canada. No illnesses or injuries have been reported to date, but the FDA advises the supplement poses a threat because sibutramine is known to "substantially increase blood pressure and/or pulse rate in some patients and may present a significant risk for patients" with a history of heart disorders or stroke, the firm says...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS100836

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel